ClinicalTrials.gg
RecruitingNCT07345169IMMUNOREAUpdated Nov 12, 2026

IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients

An observational study in Critical Illness, Intensive Care Patients and Critical Illness Requiring Intensive Care - Sepsis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionSepsisRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Eligibility revisedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
540
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris — 14 open to participants now, 15 under way, 3 of them phase 3. Sepsis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
4th of 12
540 · median 160
Started
2026
with 6 others
Observational
12 of 35
5 open now
Primary completion
2031-02
later than 14 of 14 live
Registered
31st of 35
by date

Among the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 7 that started in 2026, is one of 12 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 31st registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU). The study will establish multidimensional models predicting one-year survival and the occurrence of nosocomial infections.

Patients admitted to ICU undergo routine biological sampling. In addition to these, minimal supplementary samples will be collected for immunological and inflammatory biomarker analysis at admission, day 1, day 4, day 8, ICU discharge or day 28, and at 12 months. Additional samples may be taken during clinically significant events (nosocomial infections, complications).

03

Conditions studied

  • Critical Illness
  • Intensive Care Patients
  • Critical Illness Requiring Intensive Care - Sepsis
  • Critical Illness Requiring Intensive Care - Acute Brain Injury
  • Critical Illness Requiring Intensive Care - Major Surgery
  • Critical Illness Requiring Intensive Care - Polytrauma

Browse trials for

Keywords

  • Sepsis
  • Critical illness
  • Intensive care
  • Immunology
  • Inflammation
  • Transcriptomics
  • scRNAseq
  • Flow cytometry
  • Nosocomial infections
  • Prognosis
04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 540 is above the median of 150 across 1,166 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients (≥ 18 years old) admitted to intensive care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Admission to ICU within 24 hours

Exclusion criteria

Exclusion Criteria:

  • Moribund patient (=4)
  • Legal protection (guardianship/curatorship)
  • Uninsured patients
  • Pregnant or breastfeeding women
  • Participation in another interventional trial
  • Patients under AME
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
540 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Overall survival of patients admitted to intensive care.

    Difference in overall survival between ISU patients with different immunological and inflammatory profiles upon completion of the 12-month follow-up period.

    Time frame: 12 months

  2. Multidimensional flow cytometry leukocyte profiling

    The isolated cell samples will be analyzed to determine the absolute number and percentage of B cells, monocytes, CD4+ and CD8+ T cells, CD3+CD56+ NKT cells, and NK cells

    Time frame: Change from baseline to 12 months

  3. Inflammatory profile of ICU patients

    Inflammation-related protein biomarkers will be analyzed using Olink assay

    Time frame: Change from baseline to 12 months

Secondary outcomes

  1. Change in SOFA Score

    Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic). Minimum score = 0 maximum score = 24. Higher scores indicate greater degree of dysfunction.

    Time frame: Change from baseline to day 7

  2. Transcriptomic (scRNAseq) profiling of isolated leukocytes

    Change in the transcriptome of leukocytes isolated from blood, bronchoalveolar lavage fluid (BAL), cerebrospinal fluid (CSF), urine, and tissues, as measured by single cell RNA-sequencing using Flex technology

    Time frame: Change from baseline to12 months

08

Study locations

1 of 1 sites recruiting
  • AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement
    Paris, 75010, France
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be made available upon reasonable request, after publication of primary results, for research purposes only.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2031, 60 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 60 months is above that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Jan 15, 2026
StartActual
Feb 2, 2026was Jan 2026
Primary completionEst.
Feb 2031
CompletionEst.
Feb 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 2026→Feb 2, 2026 (actual)
Oct 7, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedPre-existing immunosuppression (active/recent cancer, hematologic disease, autoimmune disease, organ transplant, HIV)
Nov 12, 2026
Contact
Study contact changed: removed c•••@aphp.fr · •••8515. See the current contact
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement · Paris, FranceContact c•••@aphp.fr · •••8515→b•••@aphp.fr · •••8515
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedPre-existing immunosuppression (active/recent cancer, hematologic disease, autoimmune disease, organ transplant, HIV)
    Contact Study contact changed: removed c•••@aphp.fr · •••8515. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement · Paris, FranceContact c•••@aphp.fr · •••8515→b•••@aphp.fr · •••8515
    + 1 other change: verification date
  2. Oct 7, 2026
    Start date Jan 2026→Feb 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07345169
Collaborators
INSERM U942, Société Française d'Anesthésie et de Réanimation, French Society for Intensive Care, European Society of Intensive Care Medicine, ZOLL Foundation, Fondation Les Gueules Cassées
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Feb 2, 2026
Primary completion
Feb 2031 (estimated)
Completion
Feb 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Benjamin Glenn Chousterman, MD PhD
Contact
benjamin.chousterman@aphp.fr
+33 1 49 95 85 15

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion